Salud financiera de hoja de balance de Pacira BioSciences
Salud financiera controles de criterios 5/6
Pacira BioSciences tiene un patrimonio de accionistas total de $870.1M y una deuda total de $522.4M, lo que sitúa su ratio deuda-patrimonio en 60%. Sus activos y pasivos totales son $1.6B y $704.3M respectivamente. El BAIT de Pacira BioSciences es de $87.3M, por lo que su ratio de cobertura de intereses es de 9.9. Tiene efectivo e inversiones a corto plazo que ascienden a $278.6M.
Información clave
58.3%
Ratio deuda-patrimonio
US$520.33m
Deuda
| Ratio de cobertura de intereses | 51.1x |
| Efectivo | US$325.89m |
| Patrimonio | US$892.16m |
| Total pasivo | US$691.16m |
| Activos totales | US$1.58b |
Actualizaciones recientes sobre salud financiera
Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05
We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
Apr 04Recent updates
Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
Apr 04Pacira BioSciences: Higher Prices On The Horizon
Dec 20Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects
Nov 29Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly
Oct 15Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($510.0M) de PCRX superan a sus pasivos a corto plazo ($97.4M).
Pasivo a largo plazo: Los activos a corto plazo ($510.0M) de PCRX no cubren sus pasivos a largo plazo ($606.9M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (28%) de PCRX se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de PCRX ha pasado de 90.6% a 60% en los últimos 5 años.
Cobertura de la deuda: La deuda de PCRX está bien cubierta por el flujo de caja operativo (29.6%).
Cobertura de intereses: Los pagos de intereses de la deuda de PCRX están bien cubiertos por el BAIT (9.9x cobertura).